Sandra Day O Connor has lived a life of perseverance msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Getty Images
Joanna Helmuth, M.D., a neurologist at the University of California San Francisco’s Memory and Aging Center, is concerned. She’s worried about vulnerable people like vapenaysh6969, a Reddit user who recently asked for advice on the Nootropics subreddit, a message board where more than a quarter of a million people are trying to sort their way through all of the allegedly brain-boosting chemicals on the market. “Ordered some phenylpiracetam,” vapenaysh6969 wrote. “In desperate need of some motivation after being unemployed for a year now.”
Dr. Helmuth has studied the rise of pseudomedicine in products for brain health, and she believes that the industry worth a startling $7.2 billion preys on people desperate for solutions. It reminds her, in fact, of the days when nostrums were sold to cure cancer, before science-backed treatments became available. People who are worried about their memory, stress level, or employability can be particularly susceptible, b
Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
24 Apr 2021
With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick, simple ways to screen patients and determine if they have amyloid plaque in their brains. The current gold-standard diagnostics used in research amyloid PET scans and cerebrospinal fluid biomarkers are expensive, invasive, or not readily available to many patients. With that in mind, the Global Alzheimer’s Platform has launched Bio-Hermes, a collaborative study with 10 different technology companies that will assess how accurately low-cost, rapid blood-based, and digital biomarker tests detect amyloid accumulation and cognitive decline.
Bio-Hermes study will assess digital and blood-based biomarkers.